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Abstract: The short- and long-term side effects of chemotherapy limit the maximum therapeutic dose
and impair quality of life of survivors. Injury to normal tissues, especially chemotherapy-induced
cardiomyopathy, is an unintended outcome that presents devastating health impacts. Approximately
half of the drugs approved by the Food and Drug Administration for cancer treatment are associated
with the generation of reactive oxygen species, and Doxorubicin (Dox) is one of them. Dox undergoes
redox cycling by involving its quinone structure in the production of superoxide free radicals, which
are thought to be instrumental to the role it plays in cardiomyopathy. Dox-induced protein oxidation
changes protein function, translocation, and aggregation that are toxic to cells. To maintain cellular
homeostasis, oxidized proteins can be degraded intracellularly by ubiquitin-proteasome pathway or
by autophagy, depending on the redox status of the cell. Alternatively, the cell can remove oxidized
proteins by releasing extracellular vesicles (EVs), which can be transferred to neighboring or distant
cells, thereby instigating an intercellular oxidative stress response. In this article, we discuss the role
of EVs in oxidative stress response, the potential of EVs as sensitive biomarkers of oxidative stress,
and the role of superoxide dismutase in attenuating EV-associated oxidative stress response resulting
from chemotherapy.
Keywords: chemotherapy; oxidative stress; extracellular vesicles; superoxide dismutase
1. Introduction
Improved cancer treatment has raised the five-year survival rate of adult cancer patients from
49% in the late 1970s to 69% between 2005 and 2011. In childhood cancer patients, the survival rate
is even better, having improved from 58% in the 1970s to 83% by 2011. However, these gains have
been accompanied by increased risks. The longer a cancer patient lives, the greater the possibility
that complications from cancer treatment will occur. Complications can arise, in part, from oxidative
stress-induced noncancerous tissue damage, which decreases the quality of life of cancer survivors.
Treatment-related side effects such as cardiotoxicity are the third leading cause of death in adult and
childhood cancer survivors. Recurrence and secondary tumors are the first and second leading causes
of death, respectively [1]. The American Cancer Society has predicted that there will be 19 million
long-term cancer survivors in the U.S. by 2024. This immense number of survivors will necessitate an
emphasis on preventive strategies that preserve normal tissues while killing cancer cells.
Currently, 215 drugs have been approved by the Food and Drug Administration to treat cancer.
At least 50% of them can induce oxidative stress, among them anthracycline, cyclophosphamide,
cisplatin, busulfan, mitomycin, fluorouracil, cytarabine, and bleomycin [2]. Excessive reactive oxygen
species (ROS)/reactive nitrogen species (RNS) that reach the threshold of antioxidant capacity of the
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cells, as well as the accumulation of oxidized biomolecules that overwhelms biomolecular quality
controls of cells cause cytotoxicity to both cancer and normal cells. To combat against oxidative
stress-induced cytotoxicity, cells have evolved several pathways to remove oxidized toxic molecules
including proteasome-mediated degradation and autophagy, as well as removing the toxic molecules
in the form of extracellular vesicles.
Extracellular vesicles (EVs) are membranous encapsulated structures that are released from almost
all cell types. EVs are heterogeneous in size, content, and biogenesis. They are generally classified into
three types based on their biogenesis: exosomes, microvesicles, and apoptotic bodies. EVs serve as
vehicles that transfer bioactive molecules between cells and, thus, mediate cell-cell communication
during cellular stress.
This review focuses on the effects of chemotherapy on oxidative stress-induced tissue injury
as exemplified by Doxorubicin (Dox); how protein quality control is affected by Dox; the role of
extracellular vesicles in oxidized protein removal; and the relationship between extracellular vesicles
and superoxide dismutase, a major antioxidant that protects cells from oxidative damage.
2. Mechanisms of Chemotherapy-Induced Cardiomyopathy
Decades-long research that has explored the mechanisms by which Dox cause cardiomyopathy
via multiple pathways has been extensively reviewed [3]. Dox-induced cardiomyopathy engages not
only cell death-related signaling pathways in cardiomyocytes themselves, but also the intercellular
communication leading to tissue inflammation and maladaptive remodeling.
The generation of ROS and RNS is an initial event of Dox-induced cardiac tissue injury.
Mitochondria are major subcellular organelles affected by Dox, since Dox has 300–1000 fold higher
affinity to bind cardiolipin, a major component of inner mitochondrial membrane, compared to other
anionic phospholipids [4]. The redox cycling of quinone-Dox to semi-quinone radical—formed by
diverting one electron from NADH dehydrogenase at complex I and donating the electron to molecular
oxygen—gives rise to superoxide radical (O2•−) formation [5]. O2•− can also be generated by other
enzymatic reactions such as cytochrome P450 reductase, xanthine oxidase, and uncoupled nitric oxide
synthase, as well as non-enzymatic reactions from redox cycling of Dox-Fe3+ complex [6].
Manganese superoxide dismutase (MnSOD) is the major enzyme responsible for mitochondrial
O2•− removal, yielding hydrogen peroxide (H2O2) as a product. H2O2 can be further detoxified by
catalase and glutathione peroxidase. However, excessive superoxide radicals can react with other ROS
and RNS such as H2O2 and nitric oxide radical (•NO) to form more highly reactive ROS/RNS.
Aconitase is a tricarboxylic acid cycle enzyme responsible for catalyzing the conversion of
aconitate to isocitrate [7]. Aconitase contains iron-sulfur clusters that are sensitive to O2•− inactivation,
which results in the release of Fe2+ from the enzyme [8]. O2•− can also induce the release of Fe2+ from
Ferritin, an intracellular iron storage protein [9]. Fe2+ further catalyzes the interaction of O2•− with
H2O2, leading to hydroxyl radical (•OH) generation. The interaction of O2•− with •NO generates
peroxinitrite (ONOO−). ONOO− and •OH are highly reactive and can damage biomolecules such as
lipids, proteins, and nucleic acids.
Unsaturated fatty acids, major components of cellular membranes, contain carbon-carbon double
bonds, making them susceptible to ROS/RNS attack. Two major ω6 lipid peroxidation products
derived from non-enzymatic ROS/RNS attack are malondialdehyde (MDA) and 4-hydroxynonenal
(4HNE). Among the major lipid peroxidation products, 4HNE is the most toxic molecule. 4HNE
rapidly reacts with thiols and amino groups of amino acids, leading to 4HNE protein adduction. It has
been shown that protein-bound 4HNE forms early after Dox treatment. In cardiac mitochondria,
protein-bound 4HNE forms as early as 3 h following treatment, and rises to its highest level
at 6 h post-treatment. An increase in 4HNE-bound proteins occurs in mitochondria prior to
occurring in cytoplasm and the nucleus [10]. A high level of 4HNE leads to the inactivation of
the adducted proteins. Our recent study showed that during Dox treatment, 4HNE-adducted proteins
in heart tissues that are involved in the electron transport chain, such as succinate dehydrogenase
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A (SDHA), dihydrolipoamide dehydrogenase (DLD), ATP synthase subunit β (ATP5B), and NADH
dehydrogenase [ubiquinone] iron-sulfur protein 2 (NDUFS2), led to mitochondrial respiratory
dysfunction and a shift of energy production to glycolysis [11]. Furthermore, 4HNE adduction
to mitochondrial protein, as in mitochondrial apoptotic inducing factor 2 (AIFM2), can alter the protein
function from oxidoreductase to pro-apoptotic protein, leading to cardiomyocyte cell death [12].
3. Oxidized Protein Removal Pathways
Cells contain several protein quality control (PQC) mechanisms that maintain physiological
homeostasis against highly toxic oxidized protein accumulation. Those mechanisms involve protein
unfolding via endoplasmic reticulum, intracellular protein degradation via the ubiquitin-proteasome
pathway, autophagy-lysosomal pathways, and extracellular vesicles release [13,14] PQC is highly
regulated by cellular redox status. A growing body of evidence shows that Dox affects PQC in
cardiomyocytes, leading to the accumulation of oxidized proteins and eventually cell death [15–17].
3.1. Protein Unfolding System
Protein oxidative modification involves a disturbance of protein folding, resulting in aberrant
protein conformations that affect protein function, stability, and solubility [18]. Protein unfolding
occurs in the organelle endoplasmic reticulum (ER), where it serves as a first-line response against toxic
oxidized proteins. Protein unfolding is initiated by stress-sensor proteins on the ER membrane,
activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1), and protein kinase
RNA-like ER kinase (PERK). ATF6 and IRE1 activation initiates an adaptive response by upregulating
78 kDa glucose-related protein (GRP78), an ER chaperone protein responsible for regulating protein
folding. PERK activation regulates negative feedback control by inhibiting protein translation
and thus alleviating the ER workload [19]. However, excessive ER stress initiates the apoptotic
pathway mediated by caspase-12, c-Jun NH2-terminal kinase (JNK), and C/EBP homologous protein
(CHOP). A histological study of endomyocardial biopsies from patients experiencing DOX-induced
cardiotoxicity revealed extensive ER dilation [20], suggesting that ER stress is a major mechanism of
DOX-induced cardiotoxicity. Recently, a study in mice revealed that DOX activated ATF6 and IRE1 but
failed to upregulate GRP78 gene expression, leading to a shift from ER adaptive stress response to
apoptosis response [21].
3.2. Ubiquitin-Proteasome System (UPS)
The Ubiquitin-proteasome system (UPS) is responsible for removing cytosolic oxidized proteins,
which are ubiquinitated by three classes of enzymes working in concert. Ubiquitin activation
enzyme (E1) activates and transfers ubiquitin to ubiquitin conjugation enzyme (E2). Ubiquitin
ligase (E3) brings in the target substrate and transfers ubiquitin from E2 to lysine residues of the
substrate. The polyubiquitinated proteins at lysines are subsequently recognized and degraded
by the 26s proteasome. Alternately, oxidized proteins without ubiquitination can be degraded
by the 20s proteasome. UPS is highly regulated by cellular redox status. Mild oxidative stress
upregulates ubiquitination machinery and proteasome activity. However, severe oxidative stress
inhibits proteasome activity while it spares the ubiquitination systems, leading to the accumulation
of oxidized-polyubiquitinated proteins [22]. Dox is known to cause massive protein oxidation
and ubiquitination. However, the role of Dox in UPS remains controversial. A study of H9c2
cardiomyoblasts treated with 3 µM Dox for 24 h and tumor-bearing mice treated with a cumulative
dose of Dox 20 mg/kg revealed that Dox inhibits proteasome activity while it stimulates protein
ubiquitination by increasing E3 ligase expression [23]. However, another study using a lower
concentration of the therapeutic dose (0.1–5 µM) found that Dox upregulates E3 ligase, the C-terminal
of heat shock protein cognate 70-interacting protein (CHIP), and heat shock protein 70, as well as
activates 20s proteasome [24]. Nevertheless, proteasome function relies heavily on protein unfolding
for the translocation of the protein into the proteasome lumen to occur [25]. Dox that causes extensive
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oxidized protein misfolding and aggregation might compromise the UPS system despite the enhanced
proteasome activity.
3.3. Autophagy
Autophagy, literally self-digestion, contributes to the degradation of cytosolic protein aggregates
and dysfunctional organelles. Damaged components of autophagy are trafficked to lysosome
for degradation. This process can be mediated by three different pathways; macroautophagy,
microautophagy, and chaperone-mediated autophagy (CMA). Macroautophagy is characterized by
the sequestration of the cargoes by double-membrane structures, which progress to autophagosome
formation and subsequently fusion to lysosome for degradation. The process of macroautophagy
initiates with the activation of the unc-51-like autophagy activating kinase 1 (ULK-1) complex, which
further activates Beclin-1 and the vesicle-mediated vacuolar protein sorting (VPS34) complex—the
two proteins that mediate phagophore formation. Subsequently, autophagy-related gene (ATG)
proteins 5, 12, and 16 are recruited to the phagophore membrane and extend the phagophore.
The cytosolic form of microtubule-associated protein 1A/1B-light chain 3 (LC3-I) is then lipidated
with phosphatidylethanolamine to form LC3-II, which is also recruited to the phagophore membrane.
Ubiquitinated damaged protein substrate, along with p62/SQSTM1, interacts with LC3-II, all of which
are then engulfed by phagophore to form an autophagosome. The final process is the fusion of the
autophagosome with a lysosome and the degradation of the autophagosome cargoes by lysosomal
enzymes. Microautophagy directly engulfs the cytosolic component by the invagination of the
lysosomal membrane. CMA requires heat shock-cognate protein of 70 KDa (HSC70) to recognize
proteins that contain pentapeptide sequence KFERQ. HSC70-bound KFERQ-containing protein will
then bind to lysosome-associated membrane protein type 2A (LAMP-2A) on the lysosomal membrane,
which translocates the target protein into the lysosomal lumen for degradation. Blocking of autophagic
flux leads to an accumulation of oxidized proteins and organelles that are toxic to the cells.
Dox has been shown to disrupt macroautophagy and CMA. The process of autophagy
dysregulation following Dox exposure has been extensively reviewed [16,26,27]. Dox promotes
autophagosome formation by increasing LC3-II levels and ATG protein expression [28]. Dox-derived
lipid peroxidation product 4HNE is also a potent activator of aldehyde-induced autophagy [29].
Our previous study found that p53 is a key player that drives JNK1-mediated autophagosome
formation, and that p53 knockout mice are protected from Dox-induced oxidative stress in
mitochondria [30]. Recently, Bartlett and colleagues reported that Dox inhibits vacuolar ATPase
(VATPase), a proton pump on the lysosomal membrane that maintains the level of acidic pH required
for lysosomal degradation. Furthermore, the same group also found that Dox suppresses the expression
of transcription factor EB, which is a key protein governing lysosomal content and function [31].
The lysosome blocking effect leads to an accumulation of undegraded autolysosomes, resulting in
additional ROS production and cardiac injury [15].
3.4. Mitophagy
Healthy mitochondria are required for ATP generation that supports cardiac contractility.
Mitophagy, a major influence on the quality of mitochondria, relies on autophagy machinery.
Two mitophagy pathways have been described in cardiomyocytes—phosphatase and tensin
homolog-induced putative kinase 1 (PINK1)/E3 ubiquitin-protein ligase Parkin-mediated, and BCL2
interacting protein 3-like (Bnip3L)/Nip3-like protein X (NIX)-mediated pathways. The PINK1/Parkin
pathway is triggered by mitochondrial membrane depolarization, which promotes the stability
of PINK1, a serine/threonine kinase located on the mitochondrial outer membrane. PINK1 then
attracts and binds to Parkin, which subsequently ubiquitinates proteins responsible for mitochondrial
movement cessation and mitochondrial fragmentation maintenance. This ubiquitination process
targets the damaged mitochondria for lysosome degradation [32]. In contrast to the PINK1/Parkin
pathway, the Bnip3L/NIX pathway does not require mitochondrial membrane depolarization, but
Antioxidants 2017, 6, 75 5 of 17
involves phosphorylation near the LIR motif of Bnip3L, which makes it a docking site for LC3-II on
the autophagosomal membrane.
Dox affects PINK1/Parkin and Bnip3L/NIX mitophagy in different ways. Dox suppresses
PINK1/Parkin mitophagy by reducing PINK1 mitochondrial translocation. Hoshino and colleagues
reported that Dox-induced p53 activation leads to the interaction and sequestration of PINK-1
by p53 [33]. In contrast, Dox enhances Bnip3L/NIX mitophagy by inducing the mitochondrial
translocation of Bnip3L, which leads to mitochondrial depolarization and Parkin recruitment [34].
However, cytosolic sequestration of PINK1, the Parkin partner, may blunt the effect of the Bnip3L
pathway. Although Dox can either suppress or activate the upstream process of mitophagy,
Dox-induced lysosome dysfunction, which blocks the end process of mitophagy, could lead to the
retention of undigested damaged mitochondria.
4. Extracellular Vesicles
“Extracellular vesicles” is a general term that applies to membranous vesicles released from
cells into the extracellular space. EVs are composed of a lipid bilayer that encapsulates a variety of
biomolecules, including proteins, DNAs, RNAs, and carbohydrates, as well as subcellular organelles
such as mitochondria [35,36]. EV cargoes are resistant to enzymatic degradation due to the lipid bilayer
shelter. EV stability has been evaluated in various conditions. Serum EVs are stable up to 24 h at room
temperature, 1 week at 4 ◦C, and fewer than three freeze-thaw cycles. Prolonged storage beyond the
indicated time period and too many freeze-thaw cycles will cause EV rupture and content leakage [37].
Milk-derived EVs can withstand acidic pH (pH = 2.0), a short boiling temperature (105 ◦C, 15 min),
and snap freezing in liquid nitrogen. However, the same conditions significantly degrade cell-derived
EVs by 90%, 90%, and 70%, respectively [38].
Despite EV stability ex vivo, the half-life of EVs in vivo is only 2 min, due to a rapid clearance
by interaction with other recipient cells [39]. The ability of EVs released from one cell to interact with
other cells makes EVs a mediator of cell-cell communication. EVs express docking proteins on their
surface, which could be recognized by the recipient cells. The message from one cell to another could
be achieved by the interaction of EVs with the cognate receptor on the recipient cell surface, the fusion
of the EV membrane with the recipient plasma membrane, or phagocytosis and delivery of the EV
contents into the recipient cytosol [40].
EVs are heterogeneous in size, content, and biogenesis. Exosomes are the smallest EVs (50–100 nm)
and originate from the invagination of late endosomal membranes forming multiple intraluminal
vesicles (ILVs) called multivesicular bodies (MVBs). Those ILVs become exosomes when they are
released by the fusion of the MVB membrane with the plasma membrane. Microvesicles (200–1000 nm)
are derived from outward budding of the plasma membrane. Apoptotic bodies (>1000 nm) are
generated by apoptotic cell fragmentation [41].
4.1. Exosome Biogenesis
MVB formation requires machinery that not only sorts proteins into the endosomal membrane,
but also sorts proteins involved in changing membrane curvature and vesicle scission. Endosomal
sorting complexes required for transports (ESCRTs: ESCRT-0 to ESCRT-III) are the best-known protein
complexes that govern protein loading into exosomes. ESCRT-0 binds to ubiquitinated protein cargo
and distributes it to the MVB membrane. ESCRT-I associates with ESCRT-0 and ubiquitinated
proteins, and helps the membrane translocation. ESCRT-II is a bridge that connects ESCRT-I to
ESCRT-III, which is key to membrane budding and vesicle formation. In the final step, vacuolar
protein sorting-associated protein 4 (VPS4) complex dissociates ESCRT-III, thereby recycling the
ESCRTs machineries [42]. However, ESCRT is dispensable to MVB generation in some cell types.
For example, oligodendroglial cells utilize neutral sphingomyelinase to generate ceramide-forming
lipid-raft microdomain and endosomal membrane budding [43]. In lung cancer cell lines after radiation,
p53 is activated, leading to the transcription of tumor suppressor-activated pathway-6 (TSAP6),
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a transmembrane protein involved in MVB formation [44,45]. The p53-dependent MVB formation
provides a link to how DNA damage promotes exosome release.
Protein sorting into MVBs can be alternatively mediated by HSC70, a key protein that binds to
oxidized protein in CMA. However, the interactions of HSC70 with the endosomal membrane and
with the lysosomal membrane are different. HSC70 relies on the electrostatic force of its basic residues,
which attaches to acidic phospholipids on the cytosolic part of the endosomal membrane rather than
binding to LAMP2A [46].
Exosome biogenesis and autophagy are closely related. MVB cargoes are at a crossroads that
could head to degradation by lysosome fusion or be released by plasma membrane fusion. The final
destination of MVBs is governed by the Rab family of small GTPases. Rab7 directs MVBs to fuse
with lysosome, while Rab27A directs them to fuse with plasma membranes [47,48]. Thus, if one
pathway is blocked, the cargo will pass to the other pathway. For example, ESCRT depletion
in Caenorhabditis elegans enhances autophagic flux, which rescues cells from abnormal endosome
buildup [49]. Conditions that promote autophagy divert MVBs to the lysosome rather than the plasma
membrane, thus inhibiting exosome release [50]. On the other hand, autophagy defects, such as
in neurogenerative diseases, promote the release of oxidized protein aggregates via exosomes [51].
In addition, chemical or genetic inhibition of phosphoinositide kinase PIKfyve, a key enzyme in
membrane trafficking of autophagy, promotes the release of exosomes that contain proteins related to
autophagy [52].
4.2. Microvesicles (MVs) Biogenesis
Microvesicles are EVs that originate in the plasma membrane. The formation of microvesicles
involves the rearrangement of plasma membrane phospholipids and the reorganization of the
underlying cytoskeleton. An initial factor that promotes microvesicle formation is an increase
in intracellular Ca2+, which is driven by oxidative stress [53]. Increased Ca2+ inhibits inward
aminophospholipid transloase (flippase) and activates outward translocase (floppase). This aberrant
phospholipid translocation leads to an externalization of phosphatidyl serine (PS), a characteristic
of general MVs [54]. However, some MVs do not have PS on the outer membrane leaflet [55]. Ca2+
overload also activates caspases that lyse the cytoskeleton, making it dissociate from the plasma
membrane at the budding site. MV pinch-off involves a cascade of signaling that is triggered by
GTP-binding protein ADP-ribosylation factor 6 (ARF6). ARF6 activates phospholipase D, leading to
phosphatidic acid generation, which recruits extracellular signal-regulated kinase (ERK) to the plasma
membrane. ERK subsequently phosphorylates myosin light-chain kinase (MLCK), which further
phosphorylates the myosin light chain (MLC). This signaling cascade results in actomyosin-based
contraction at the neck of the bud, leading to MV release [56].
4.3. Apoptotic Bodies Biogenesis
Unlike exosomes and MV formation, apoptotic bodies are generated by dead cells. However,
a common pathway observed in both apoptotic body formation and MV formation is MLC
phosphorylation, which is responsible for membrane protrusion. Instead of the ARF-6-mediated
process, membrane blebbing of apoptotic cells initiates caspase-3 activation, which cleaves and activates
Rho-associated coiled-coil protein kinase 1 (ROCK-1), an enzyme that phosphorylates MLC [57].
Because caspase activation causes DNA cleavage and cytochrome c release from mitochondria,
the remnants of this process, such as nuclear DNA and mitochondrial fragments, can be found
in apoptotic bodies.
4.4. EVs Serve as a Bypass Highway for Oxidized Proteins Removal during Dox-Induced Cardiotoxicity
Dox generates extensive quantities of oxidized and ubiquitinated proteins while it disrupts
multiple pathways of protein quality control as discussed above. Because EV biogenesis and protein
quality control pathways are interconnected, EVs serve as an alternative pathway to remove toxic
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proteins from cells during Dox-induced oxidative stress. Indeed, Dox can promote EV release in
several ways. Dox activation of p53 can increase MVB production via TSAP6 activation [44,45].
In addition, Dox disrupts Ca2+ homeostasis in cardiomyocytes by interfering with the electron transport
chain, leading to the potential collapse of the mitochondrial membrane [58]. Inability to maintain
the mitochondrial membrane potential inhibits Ca2+ influx into mitochondria, which results in an
elevation of cytosolic Ca2+, a key event that induces MV release. Lipid peroxidation by Dox may affect
membrane curvature and promote EV formation, as evidenced by the photooxidation of the artificial
lipid membrane, inducing the alteration of its physical property, in which the hydroperoxyl group
increases the area of the lipid membrane, thus forming membrane budding [59]. The effect of Dox on
protein quality control pathways as well as EV biogenesis is summarized in Figure 1.
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Dox redox cycling at complex I leads to excessive ROS and RNS generation in mitochondria,
which leads to biomolecule oxidation (1). 4HNE is a reactive lipid peroxidation product that can adduct
to proteins and inactivate protein function (2). Oxidized proteins as well as 4HNE-adducted proteins
are subject to degradation by th protein quality control p thways, includi g pro ei unfolding, the
ubiquitin-proteasome pathway, and autophagy. Severe protein oxidati n due to Dox insults generates
bulky misfolded proteins, which overwhelm proteasome degradation, thus forming protein aggregates
(3). Autophagy is a major pathway to remove and recycle protein aggregates, as well as damaged
organelles such as mitochondria. Dox inhibits VATPase, a proton pump that maintains lysosomal
pH, as well as LAMP2A, a membrane transporter of oxidized protein into the lysosomal lumen for
degradation (4). The lysosomal dysfunction leads to an accumulation of oxidized proteins, which
can be alternatively sorted into MVBs by ESCRT complexes (5), as well as HSC70 (6). Dox-induced
DNA damage activates p53, which further upregul tes TSAP6, an endosomal membrane protein
responsib for MVB formation (7). Exos mes are generated by the fusion of MVBs with he plasma
membrane, which releases intral min l vesicles to the extracellular space (8). Dox blocks mitophagy
via p53-mediated PINK1 sequestration into cytosol, thus preventing autophagosome formation (9).
Dysfunctional mitochondria that cannot be cleared by autophagy accumulate (10). Meanwhile,
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mitochondrial dysfunction induces Ca2+ retention in the cytoplasm (11), which in turn inhibits flippase
and activates floppase (12). PS externalization occurs due to floppase activity (13). Increase in cytosolic
Ca2+ also activates caspases, which cleaves the cytoskeleton and dissociates the membrane from the
underlying structure, forming MVs (14).
Since the mechanisms by which Dox promotes EV release are based primarily on oxidative stress,
it follows that this concept can be applied to other chemotherapeutic agents that generate ROS/RNS
as well. In fact, Hall and colleagues found a significant increase in endothelial-derived MVs in the
blood of multiple myeloma patients treated with cyclophosphamide, thalidomide/lenalidomide, and
dexamethasone comparing to baseline [60]. In addition, cancer cells exploit EVs to remove intracellular
chemotherapeutic drugs and promote chemo-resistant phenotypes. Recently, Muralidharan-Chari
and colleagues reported that human pancreatic cancer cells release MVs to expel Gemcitabine—a
chemotherapy that inhibits DNA synthesis. The ability of the cells to release MVs for Gemcitabine
clearance correlated with the degree of drug resistance, and the inhibition of MV release sensitized the
cells to Gemcitabine [61].
4.5. EVs as a Biomarker for Oxidative Stress
For many reasons, EVs are more attractive for biomarker discovery than conventional serum
biomarkers. In addition to their stability and ability to carry many kinds of biomolecules, as discussed
above, EVs are abundant in various body fluids, including blood, urine, saliva, milk, lymph, ascites,
and amniotic fluids. EVs that are released from viable tissues in the form of exosomes and MVs serve
as useful tools of early markers of tissue injury that are detectable prior to cell death. Since EVs are
highly associated with tissue redox status, a study of oxidatively modified molecules will be beneficial
for biomarker discovery of oxidative stress-mediated diseases, especially in chemotherapy-induced
tissue injury, where early cardioprotective intervention is a goal. Figure 2 shows potential EV cargo
that could be used as a biomarker for oxidative stress and potential methods to identify those markers.
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4.6. Role of EVs in Oxidative Stress Response
EVs play a key role in mediating cell-cell communication. They shuttle bioactive lipids, mRNA,
and miRNA, as well as signaling proteins that drive biological changes in recipient cells. EVs have
advantages over other types of intercellular communication because the signaling molecules inside
them are protected from enzymatic degradation. Thus, the messages can be delivered to sites away
from the releasing spot. The messages can also be delivered with high specificity to recipient cells via
receptor-mediated endocytosis [62]. Intercellular communication via EVs is critical to the progression of
many oxidative stress-related diseases, among them: cancer-microenvironment crosstalk—a key event
in cancer progression and metastasis [63]; spreading toxic protein aggregates in neurodegenerative
diseases [64]; and carrying damage and pathogen-associated molecular patterns (DAMPs and PAMPs),
autoantigens, and proinflammatory cytokines to activate immune cells in inflammatory diseases [65].
In this review, we discuss the role of EVs in the context of oxidative stress.
Table 1 summarizes the effect on recipient cells of EVs released under different oxidative stress
conditions. Briefly, oxidative stress conditions affect the contents of EVs. Those contents can induce
oxidative stress response in recipient cells either by helping to protect the releasing cells against further
injury or by exacerbating the injury. Although EVs serve as a compensatory mechanism that deal
with proteotoxicity, the consequences of proteotoxic cargo transference to neighboring cells can be
detrimental. Malik et al. showed that ROS induction in adult rat cardiomyocytes treated with ethanol
or brief hypoxia/reoxygenation condition leads to HSP60-containing exosome release, as HSP60
causes cardiomyocyte apoptosis [66]. However, the spreading of HSP60 by exosomes to neighboring
cells could activate Toll-like receptor 4 (TLR4)-mediated apoptosis in recipient cells [67]. In contrast,
Eldh et al. reported that mRNA profiling in exosomes changes when mast cells are treated with H2O2
and the exosomal mRNA help mast cells tolerate higher doses of H2O2 [68]. Retinal pigment epithelial
cells treated with ethanol release exosomes that contain vascular endothelial growth factor receptor as
well as the mRNA of the protein and the exosomes promotes angiogenesis [69].
EVs are well-known to function as an immunomodulators. EVs can present cellular peptide
antigens on their surface with major histocompatibility complex (MHC) class I and class II molecules.
The peptide antigen can activate T-cells directly or indirectly via transferring to antigen-presenting
cells. Accumulating evidence indicates that EVs released under oxidative stress conditions can
stimulate immune cells. Stress EVs which are generated by treating HEK293 cells with Ca2+
ionophore (A23187) or by treating synthetic EVs with 15-lipoxygenase and Fenton reaction contain
lipid peroxidation products on their surfaces. These stress EVs activate TLR4-mediated NFκB
signaling and pro-inflammatory cytokine release from macrophages [70]. Plasma of mice fed a
high-fat diet releases MVs containing oxidized mtDNA, which can induce TNFα and IL-6 production
through TLR9 activation [71]. Oxidative stress in an alcoholic hepatitis model contains mtDNA in
hepatocyte-derived MVs, which can also activate TLR9 and promote neutrophilic inflammation [72].
Another alcoholic hepatitis model presented hepatocyte release exosomes with miR-122, a liver-specific
miRNA. The miR-122 in exosomes is biologically active in that it can inhibit heme oxygenase-1,
making the monocyte more sensitive to LPS-induced TNFα and IL-1β production [73]. Mouse and
human hepatocytes treated with palmitate to induce lipotoxicity release MVs that express TNF-related
apoptosis-inducing ligand (TRAIL) on their surface, which were recognized by death receptor 5 on
macrophages, resulting in IL-6 release [74]. Immune cells can receive EV-induced cytokine production
signals from non-immune cells. Wang et al. recently reported that myocardial infarction induces
macrophages to release exosomes containing miR-155, which can transfer to cardiac fibroblasts.
This leads to the downregulation of the suppressor of cytokine signaling 1 (SOCS1)—a negative
regulator of cytokine signaling—thus promoting cardiac inflammation [75]. However, a recent study
from Cambier et al. found that the most abundant RNA in EVs released during myocardial infarction
from cardiosphere-derived cells are Y RNA fragments, small non-coding RNAs. The delivery of Y RNA
to macrophages upregulates IL-10 and protects cardiac tissue from ischemia/reperfusion injury [76].
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Table 1. Role of oxidative stress-related EVs on cell viability and tissue inflammation.
Cell/Tissue Type of Origin EV Type Oxidative Stress Condition Oxidative Stress-Related Cargo Effect Reference
Cardiomyocytes Exosomes Ethanol, hypoxia/reoxy-genation HSP60 TLR4-mediated apoptosis Heiserman et al. [67]
Mast cells Exosomes H2O2 mRNA H2O2 tolerance Eldh et al. [68]
Retinal pigment epithelial cells Exosomes Ethanol VEGF protein and mRNA Angiogenesis Atienzar-Aroca et al. [69]
HEK293 cells Exosomes + MVs Ca2+ ionophore (Lipoxygenase stimulator) Oxidized phospholipids TLR4-mediated NFκB activation Mancek-Keber et al. [70]
Liver MVs High fat diet treated mice (NASH model) Oxidized mtDNA TLR9-induced TNFα, IL-6 production Garcia-Martinez et al. [71]
Liver MVs Chronic-plus-binge alcohol drinking mtDNA TLR9-mediated neutrophilic inflammation Cai et al. [72]
Liver Exosomes Alcoholic hepatitis miR-122 Sensitize monocytes to LPS Momen-Heravi et al. [73]
Liver MVs Saturated fatty acid-induced lipotoxicity TRAIL DR5-dependent macrophage activation Hirsova et al. [74]
Macrophage Exosomes Myocardial infarction miR-155 Fibroblast inflammation Wang et al. [75]
Cardiosphere-derived cells EVs Myocardial infarction Y RNA fragment IL-10 expression and secretion Cambier et al. [76]
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5. Role of Superoxide Dismutase in EV-Associated Oxidative Stress Response
Superoxide dismutase (SOD) is a compartmentalized ROS detoxifying enzyme that catalyzes
the dismutation of O2•− to H2O2 and O2 [77,78]. Three isoforms of SOD have been characterized
in mammals. SOD1 (CuZnSOD) is a homodimer that contains Cu and Zn at the catalytic cite.
CuZnSOD is located ubiquitously in cytoplasm, the mitochondrial intermembrane space, nucleus, and
lysosome. SOD2 (MnSOD) is a Mn-containing homotetramer enzyme with a mitochondrial localization
sequence that makes it reside in the mitochondrial matrix. SOD3 (ECSOD) is a Cu- and Zn-containing
homotetramer enzyme localized on the cell surface by the interaction of its C-terminal region with
heparin and other extracellular matrix proteins [79,80]. ECSOD can be detected in body fluids such
as plasma, lymph, ascites, synovial fluid, and cerebrospinal fluids [81,82]. SOD plays a role in cell
signaling under physiological as well as pathological conditions. Recent studies have begun to reveal
the interplay between SOD and the EV pathway. A discussion of the relationship between SOD and
EVs in the context of EV-associated oxidative stress response follows.
5.1. SOD1
The SOD1 gene is located on chromosome 21 (21q22.1 region). The SOD1 activity of a person with
Down syndrome (trisomy 21) is 50% higher than in the normal population. Although the mechanism of
how SOD1 promotes the Down syndrome phenotype is unknown, one possible explanation is the out
proportion of SOD1 activity over glutathione peroxidase 1 activity, which leads to the overproduction
of H2O2—a key senescence mediator [83]. The well-established link between SOD1 and human disease
is typified by the development of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease
characterized by the progressive loss of motor neurons in the corticospinal tract involving the brain,
brainstem, and spinal cord. SOD1 mutations account for 1–4% of sporadic ALS patients and 20% of
familial ALS patients [84]. SOD1 mutation interferes with protein stability and folding, which leads to
aggregate formation [85]. The aggregated SOD1 can be transferred to other neurons by contiguous
propagation to the neighboring neurons or by the network propagation of synaptic transmission [86].
Grad and colleagues found that aggregated SOD1 can be released extracellularly with or without
exosome association. The free SOD1 or the exosome-associated SOD1 can be taken up by recipient cells.
However, many questions remain to be clarified in exosome-mediated SOD1 transfer. For instance,
how is aggregated SOD1 sorted into MVBs, and is the SOD1 in the exosomes degraded in the recipient
cells by the lysosomal pathway, or does it cause proteotoxicity in the recipient cells?
5.2. SOD2
SOD2 is located exclusively in mitochondria. Its major role is to protect mitochondria from the
damaging effects of O2•− (reviewed comprehensively in [87]). Complete SOD2 knockout in mice is
lethal in early post-natal life due to dilated cardiomyopathy [88]. Life-long heterozygous deletion of
SOD2 in mice reduces 50% of SOD2 activity and leads to oxidative damage in all tissues, as evidenced
by the elevation of 8-OHdG in nuclear and mtDNA. Although aging is not affected by partial SOD2
deletion, the mice have a two-time higher incidence of developing tumors and 80% have multiple
tumors, including lymphoma, hemangioma, adenocarcinoma, and pituitary adenoma [89].
Excessive ROS generation from mitochondria is a major mechanism of Dox-induced cardiotoxicity.
Our lab previously discovered that SOD2 overexpression protects heart tissue from Dox-induced
mitochondrial injury [90]. In those animals, mitochondrial complex I is spared from O2•− insult [91].
Mitochondrial iron is a critical mediator of cardiotoxicity from Dox. Dexrazoxane, an iron-only chelator
that is FDA-approved for use as a cardioprotective agent against Dox toxicity, is more effective than
other iron chelators since it can reduce mitochondrial iron [92]. SOD2 affects mitochondrial iron in a
manner similar to the effect of dexrazoxane. In mice, the loss of SOD2 from erythroid progenitor cells
accumulates mitochondrial iron, leading to protein oxidation and membrane deformity—a phenotype
similar to ringed sideroblast in hemolytic anemia [93].
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As discussed above, oxidative stress and impaired protein quality control drive EV release, which
in turn can promote further tissue damage and tissue inflammation. Although the direct effect of SOD2
on EV oxidative stress response has not yet been investigated, we speculate that SOD2, which limits
ROS production, can reduce oxidative stress-related tissue injury from the first wave of chemotherapy
insult, as well as prevent the second wave of injury mediated by damaging cell-derived EVs.
5.3. SOD3
SOD3 is a secretory CuZnSOD. The human SOD3 gene is localized on the 4p-q21 region of
chromosome 4 [94]. It shares 60% homology with the SOD1 gene, but very low homology with the
SOD2 gene. Human SOD3 mRNA is highly enriched in certain tissues, including heart, placenta,
pancreas, and lung, and less enriched in kidney, skeletal muscle, liver and brain tissue [95]. As it
is located on cell surfaces and in the extracellular matrix, SOD3 plays a major protective role
against oxidative damage in the extracellular environment. •NO in the extracellular environment is
crucial for maintaining cardiovascular homeostasis. •NO regulates vascular tone; inhibits platelet
aggregation and leukocyte adhesion; and prevents vascular inflammation. O2•− generated by Xanthine
oxidase, NADPH oxidase, and uncoupled endothelial nitric oxide synthase interacts with •NO
forming ONOO−, which in turn oxidizes various biomolecules, leading to vascular dysfunction.
SOD3 promotes the bioavailability of •NO by removing the inhibiting O2•−, thus helping to maintain
vascular function [80].
A recent study by Iversen and colleagues revealed that SOD3 can also present in the intravesicular
compartment of neutrophils in a resting state and be released as a cargo of EVs when the neutrophil is
stimulated by formyl-methionyl-leucyl-phenylalanine or phorbal 12-myristate 13-acetate. The function
of SOD3 in EVs is preserved as EVs containing SOD3 can reduce O2•− in the extracellular space [96].
Indeed, neutrophils lack SOD3 mRNA. Thus, SOD3 in vesicles might originate from other cells, transfer
to neutrophil plasma membranes, and subsequently be stored in endosomes, ready for secretion when
needed. However, the original source of transferred SOD3 and the mechanism of how SOD3 is taken
up by neutrophils into secretory vesicles have not been investigated. Understanding the mechanism of
SOD3 transfer and storage by EVs may help develop a new therapeutic intervention to use EVs as a
vehicle to transfer SOD3 to the tissues that require this antioxidant enzyme but have limited capacity
to generate their own SOD3.
6. Conclusions and Future Direction
Cells release EVs as a compensatory mechanism to remove toxic oxidized protein to maintain
homeostasis. Many lines of evidence emphasize the relationship between EVs and oxidative stress.
However, the precise mechanisms of how excessive ROS affects the machineries involved in EV
biogenesis remain to be elucidated. The study of oxidized molecules in EVs is attractive for novel
biomarker discoveries of oxidative stress-related diseases. EV-mediated oxidative stress response
could be beneficial or detrimental to the releasing cells. SODs can be transferred via the EV pathway
and their antioxidant functions preserved in recipient cells. We predict that overexpression of SOD
or treatment with SOD mimetics will prevent the formation of EVs containing oxidative damage
markers. It is possible that EVs will serve as sensitive and practical biomarkers to predict antioxidant
capacity against chemotherapy of individual patients. Further intensive investigations are needed to
decipher the complex relationship between EVs and SOD in order to gain a clearer picture for future
therapeutic interventions.
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